文献速递慢性静脉疾病静脉血栓栓塞

抗凝治疗时长与下肢浅静脉血栓患者静脉血栓栓塞症风险相关性的系统评价与荟萃分析

A systematic review and meta-analysis for the association between duration of anticoagulation therapy and the risk of venous thromboembolism in patients with lower limb superficial venous thrombosis.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2023-11-24

该系统评价与荟萃分析纳入24项研究共12,341例下肢浅静脉血栓患者,按全身抗凝治疗时长分组,评估静脉血栓栓塞症发生率。结果显示抗凝31至45天时静脉血栓栓塞症和浅静脉血栓进展或复发率最低,短期治疗(≤14天)发生率最高,延长全身抗凝与静脉血栓栓塞症发生率降低的趋势相关。

要点

  • 抗凝31至45天组静脉血栓栓塞症发生率最低,为每100患者年16.2次(95%CI 10.4-23.3)。
  • 抗凝≤14天组静脉血栓栓塞症发生率最高,为每100患者年59.7次(95%CI 37.7-86.4)。
  • 大出血率与抗凝时长无关,未超过每100患者年0.5次。

核心结论

  • 延长全身抗凝治疗与下肢浅静脉血栓患者静脉血栓栓塞症发生率降低的趋势相关。

研究设计与样本

  • 系统评价与荟萃分析,检索Medline和Cochrane Library数据库(2023年9月),纳入报告接受任何抗凝治疗患者随访≥45天静脉血栓栓塞症发生率的文献,共纳入24项研究(10项随机对照试验和14项队列研究),合计12,341例患者。

主要发现

  • 抗凝31至45天组静脉血栓栓塞症发生率为每100患者年16.2次(95%CI 10.4-23.3),浅静脉血栓复发或进展率为每100患者年8.2次(95%CI 3.1-15.8),均为最低。
  • 抗凝15至30天组深静脉血栓发生率为每100患者年5.5次(95%CI 2.8-9.1),肺栓塞发生率为每100患者年0.9次(95%CI 0.5-1.3),均为最低。
  • 抗凝≤14天组静脉血栓栓塞症发生率为每100患者年59.7次(95%CI 37.7-86.4),深静脉血栓为13.7次(95%CI 9.6-18.4),肺栓塞为3.1次(95%CI 1.4-5.6),均为最高。
  • 大出血率与抗凝时长无关,未超过每100患者年0.5次;临床相关非大出血或小出血率在抗凝31至45天组最高,为每100患者年14.2次(95%CI 5.5-26.8)。
  • 静脉血栓栓塞症最常见危险因素包括男性、癌症、深静脉血栓/肺栓塞/浅静脉血栓个人史及非曲张静脉血栓形成。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to determine the association between the duration of systemic anticoagulation therapy (ACT) and the risk of further venous thromboembolism (VTE) in patients with superficial venous thrombosis (SVT). METHODS: A systematic review and meta-analysis were performed using searches of Medline and Cochrane Library databases in September 2023. Papers that provided VTE incidence within mid-term follow-up of ≥45 days in patients who received any ACT were included. Patients were categorized into subgroups according to the course of treatment: (1) no ACT (0 days); (2) ACT of ≤14 days; (3) ACT of 15 to 30 days; (4) ACT of 31 to 45 days; and (5) ACT of >45 days. Reported events were transformed to events per 100 patient-years, and a random-effects model was used to calculate pooled rates for proportions. The primary outcome (VTE) was a combination of SVT progression or recurrence with the occurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE). Secondary outcomes included major and clinically relevant non-major or minor bleeding. RESULTS: Twenty-four studies (10 randomized controlled trials and 14 cohort studies) combining outcomes in 12,341 patients were included in the quantitative synthesis. Minimum VTE and SVT recurrence or progression rates were observed with the ACT duration of 31 to 45 days of 16.2 (95% confidence interval [CI], 10.4-23.3) and 8.2 (95% CI, 3.1-15.8) events per 100 patient-years, respectively. Minimum DVT and PE rates observed with the treatment duration of 15 to 30 days were 5.5 (95% CI, 2.8-9.1) and 0.9 (95% CI, 0.5-1.3) events per 100 patient-years, respectively. Short-term treatment of ≤14 days was associated with the highest rates of VTE of 59.7 (95% CI, 37.7-86.4), DVT of 13.7 (95% CI, 9.6-18.4), and PE of 3.1 (95% CI, 1.4-5.6) events per 100 patient-years. Major bleeding rates were unrelated to the duration of ACT and did not exceed 0.5 events per 100 patient-years. The highest rate of clinically relevant non-major or minor bleeding was observed with ACT duration of 31 to 45 days of 14.2 (95% CI, 5.5-26.8) events per 100 patient-years. The most common risk factors for VTE included male sex, cancer, personal history of DVT, PE, or SVT, and thrombosis of non-varicose veins. CONCLUSIONS: Prolonged systemic anticoagulation is associated with the tendency to decrease VTE rates in patients with lower limb SVT.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Lobastov K, Dubar E, Schastlivtsev I, et al. A systematic review and meta-analysis for the association between duration of anticoagulation therapy and the risk of venous thromboembolism in patients with lower limb superficial venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 38008180. doi:10.1016/j.jvsv.2023.101726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。